Home Stock

Stock Research: Charles River Laboratories

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Charles River Laboratories

NYQ:CRL US1598641074
72
  • Value
    40
  • Growth
    56
  • Safety
    Safety
    75
  • Combined
    62
  • Sentiment
    93
  • 360° View
    360° View
    72
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Charles River Laboratories International, Inc. is a drug development company that provides essential products and services globally to accelerate research and drug development. Its main businesses include Research Models and Services (Research Models, Research Model Services, Cell Solutions), Discovery and Safety Assessment (regulated and non-regulated DSA services, therapeutic discovery and optimization, in vitro and in vivo studies, laboratory support, consulting), and Manufacturing Solutions (Microbial Solutions, Biologics Solutions). It operates around the globe. In the last fiscal year, the company had 18600 employees, a market cap of $7584 million, profits of $1408 million, and revenue of $4050 million.

more

ANALYSIS: With an Obermatt 360° View of 72 (better than 72% compared with alternatives), overall professional sentiment and financial characteristics for the stock Charles River Laboratories are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Charles River Laboratories. The consolidated Growth Rank has a good rank of 56, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 56% of competitors in the same industry. The consolidated Safety Rank at 75 means that the company has a financing structure that is safer than 75% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 93, which means that professional investors are more optimistic about the stock than for 93% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 40, meaning that the share price of Charles River Laboratories is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 60% of alternative stocks in the same industry. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Pro Holdings
Country USA
Industry Life Sciences Tools & Services
Size X-Large
Website criver.com
Index
D.J. US Health Care
S&P 500
Charles River Laboratories stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
40 63 51 37
Growth
56 29 31 55
Safety
Safety
75 42 20 12
Sentiment
93 19 86 43
360° View
360° View
72 12 34 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
19 3 70 57
Opinions Change
50 13 36 60
Pro Holdings
n/a 74 88 21
Market Pulse
100 26 67 58
Sentiment
93 19 86 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
40 63 51 37
Growth
56 29 31 55
Safety Safety
75 42 20 12
Combined
62 23 12 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
86 63 57 67
Price vs. Earnings (P/E)
17 73 68 45
Price vs. Book (P/B)
70 53 40 22
Dividend Yield
1 1 1 1
Value
40 63 51 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
24 42 23 42
Profit Growth
91 22 48 57
Capital Growth
84 63 25 30
Stock Returns
24 25 61 81
Growth
56 29 31 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
18 28 20 22
Refinancing
91 31 9 17
Liquidity
78 55 71 56
Safety Safety
75 42 20 12

Similar Stocks

Discover high‑ranked alternatives to Charles River Laboratories and broaden your portfolio horizons.

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Resideo Technologies

NYQ:REZI
Country: USA
Industry: Building Products
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews